HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Shasun Buys Nuprin, DSM And GSK Earnings, Ad Claims Referred To FTC

This article was originally published in The Tan Sheet

Executive Summary

Shasun acquires ibuprofen products; DSM predicts nutrition sales will increase; GSK sales fall on supply chain trouble; Nature’s Medicine Associates’ ad referred to FTC; Heinrich co-sponsors designer steroid bill; and AHPA eases botanical identification burden.

Advertisement

Related Content

Hi-Tech CEO Wheat Arrested In FDA Investigation Of Steroid-Spiked Supplements
Trump Administration May Relax Supplement Industry Oversight, But Heighten Trade Concerns
Alli Labels In U.S. Add Seizure Advisory Similar To E.U. Change
Alli Labels In U.S. Add Seizure Advisory Similar To E.U. Change
In Brief: Lornamead Settles On Lice Claims; DASCA Introduced In House; FDA Warns Supplement Firms
In Brief: Lornamead Settles On Lice Claims; DASCA Introduced In House; FDA Warns Supplement Firms
Alli Recall Could Help Mitigate Reputation Damage In Face Of Tampering
SCOLR Ready To Answer FDA Questions On 12-Hour Pseudoephedrine ANDA

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS106893

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel